Arcutis Appoints Interim Chief Financial Officer (CFO)
18 Agosto 2023 - 5:30PM
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early
commercial-stage biopharmaceutical company focused on developing
meaningful innovations in immuno-dermatology, today announced that
John W. Smither, who served as Arcutis’ first Chief Financial
Officer (CFO) from 2019 to 2021, has been appointed interim CFO
effective August 31. He is replacing Scott Burrows, who is leaving
the Company as of such date to pursue an external opportunity.
“We are delighted that John has agreed to step in as interim
CFO. He brings an incredible depth and breadth of both financial
acumen and dermatology experience from his 25+-year career in the
pharmaceutical industry, culminating in five successive CFO roles
including his previous stint at Arcutis,” said Frank Watanabe,
President and Chief Executive Officer of Arcutis. “On behalf of our
Board and team, I would like to thank Scott for his tremendous
contributions to Arcutis. We are grateful for his leadership, which
was critical to the evolution of our financial organization in
order to support the establishment and growth of our commercial
operations in the United States and Canada, and we wish him success
in his future endeavors.”
“I am excited to rejoin the Arcutis team as interim CFO and
continue the Company’s success delivering new innovations for
serious skin diseases,” added John Smither. “With the first topical
phosphodiesterase-4 inhibitor approved for plaque psoriasis and the
potential approval of roflumilast foam for seborrheic dermatitis
anticipated later this year, the Company is well positioned to
further its leadership in medical dermatology.”
“It’s been a privilege to be a part of Arcutis’ growth over the
last four years,” said Scott Burrows. “The Company has made great
progress with the launch of ZORYVE® (roflumilast) cream 0.3% in
plaque psoriasis and has the potential of multiple subsequent
approvals and launches in the next 18 months. I wish the entire
team great success in the future.”
As Arcutis’ first CFO, John led the successful IPO in 2020, and
built the finance function from the ground up. Prior to Arcutis,
Mr. Smither served as CFO for Sienna Biopharmaceuticals from
January 2016 to March 2017 and again from March 2018 to April 2019.
From October 2017 to April 2018, he was interim CFO for Kite Pharma
during its integration with Gilead, and prior to that, was CFO at
Unity Biotechnology from January 2016 to 2017. Earlier, he served
as CFO of Kythera Biopharmaceuticals, Inc. from November 2007 until
it was acquired by Allergan in October 2015 for $2.1 billion. In
his various CFO positions, Mr. Smither oversaw multiple private and
public financing rounds, including Kythera’s initial public
offering, and initial IPO preparations at Unity and Sienna. He also
serves on the Board of Directors of eFFECTOR Therapeutics, Applied
Molecular Transport Inc. and NewAmsterdam Pharma Company N.V.
About ZORYVE®ZORYVE
(roflumilast) cream 0.3% is indicated for topical treatment of
plaque psoriasis, including intertriginous areas, in patients 12
years of age and older.
IMPORTANT SAFETY INFORMATION The use of ZORYVE
is contraindicated in patients with moderate to severe liver
impairment (Child-Pugh B or C).
The most common adverse reactions (≥1%) include diarrhea (3%),
headache (2%), insomnia (1%), nausea (1%), application site pain
(1%), upper respiratory tract infection (1%), and urinary tract
infection (1%).
Please see full Prescribing Information.
About ArcutisArcutis Biotherapeutics, Inc.
(Nasdaq: ARQT) is an early commercial-stage medical dermatology
company that champions meaningful innovation to address the urgent
needs of individuals living with immune-mediated dermatological
diseases and conditions. With a commitment to solving the most
persistent patient challenges in dermatology, Arcutis has a growing
portfolio that harnesses our unique dermatology development
platform coupled with our dermatology expertise to build
differentiated therapies against biologically validated targets.
Arcutis’ dermatology development platform includes a robust
pipeline with multiple clinical programs for a range of
inflammatory dermatological conditions including scalp and body
psoriasis, atopic dermatitis, seborrheic dermatitis, and alopecia
areata. For more information, visit www.arcutis.com or
follow Arcutis on LinkedIn, Facebook, and Twitter.
Forward-Looking StatementsArcutis cautions you
that statements contained in this press release regarding matters
that are not historical facts are forward-looking statements. These
statements are based on the Company’s current beliefs and
expectations. Such forward-looking statements include, but are not
limited to, statements regarding the potential for ZORYVE to
simplify disease management for care of plaque psoriasis; the
potential of real-world use results of roflumilast cream, as well
as the commercial launch of ZORYVE in plaque psoriasis, and the
timing of regulatory filings and potential approvals for a number
of dermatology indications for roflumilast in the United States and
Canada. These statements are subject to substantial known and
unknown risks, uncertainties and other factors that may cause our
actual results, levels of activity, performance, or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. Risks and uncertainties that
may cause our actual results to differ include risks inherent in
our business, reimbursement and access to our products, the impact
of competition and other important factors discussed in the "Risk
Factors" section of our Form 10-K filed with U.S. Securities and
Exchange Commission (SEC) on February 28, 2023, as well as any
subsequent filings with the SEC. You should not place undue
reliance on any forward-looking statements in this press release.
We undertake no obligation to revise or update information herein
to reflect events or circumstances in the future, even if new
information becomes available. All forward-looking statements are
qualified in their entirety by this cautionary statement, which is
made under the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995.
Contacts:MediaAmanda Sheldon,
Head of Corporate Communicationsasheldon@arcutis.com
InvestorsEric McIntyre, Head of Investor
Relationsemcintyre@arcutis.com
Arcutis Biotherapeutics (NASDAQ:ARQT)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Arcutis Biotherapeutics (NASDAQ:ARQT)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024